No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
NVCR Novocure
- 30.800
- +0.400+1.32%
Close Dec 20 16:00 ET
- 30.800
- 0.0000.00%
Post 20:01 ET
3.33BMarket Cap-22.16P/E (TTM)
31.520High30.330Low1.82MVolume30.330Open30.400Pre Close56.20MTurnover1.85%Turnover RatioLossP/E (Static)108.20MShares34.13052wk High9.24P/B3.03BFloat Cap11.70052wk Low--Dividend TTM98.51MShs Float232.760Historical High--Div YieldTTM3.91%Amplitude5.950Historical Low30.868Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
Novocure Is Maintained at Overweight by Piper Sandler
NovoCure Analyst Ratings
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
Heat List
US
Overall
Symbol
Price
% Chg
No Data